Key details:
1. The offering, which includes 6,666,667 shares, is expected to close July 1.
2. In addition to commercialization, Motus GI plans to use the proceeds from the stock sales to continue research and development of the Pure-Vu system, as well as to license additional technologies.
3. MotusGI granted the underwriters a 30-day option to purchase 1 million additional shares.
More articles on gastroenterology:
GI outpatient department converts to ASC & 4 more must-read articles
Exact Sciences opens new laboratory, can process up to 7M tests — 3 insights
Physicians Endoscopy partners with Cleveland hospital & more: 3 GI company key notes
